Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study found

Story checked

Injectable glucose sensor component matches pricier alternative at one-tenth the cost (opens in a new tab)

medicalxpress.com · 2026-11-03

Short answerEvidenceSource

Short answer

Supported

Supported.

The story matches what the study reports.

  • 5 supported

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Supported

Every claim holds up. All five claims match what the study reports.

  • 5 supported
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

5 claims in this story

Showing all 5 claimsChoose a verdict to focus the list.

Claim 1 of 5SupportedTexas A&M University researchers identified a lower-cost component for an experimental injectable glucose sensor that matched a pricier alternative at roughly one-tenth the cost.View evidenceHide evidence

As statedone-tenth the cost

Why this verdict

The abstract-level profile supports that the researchers developed an experimental, intended-injectable nonenzymatic NIR glucose-sensing assay using β-mannopentaose and compared it with an α-mannopentaose control reported as about 10× costlier. The profile reports comparable responsiveness/binding affinity and a broader β-anomer buffer dynamic range. The headline phrasing is somewhat compressed, but it does not outrun the paper evidence so long as 'matched' is read as comparable in the reported in vitro assay performance.

1

Study evidence

Developed an in vitro, nonenzymatic NIR fluorescence glucose sensing assay composed of PEGylated-ConA and Cy5.5-β-mannopentaose intended for injectable/minimally invasive continuous monitoring.

“novel, fully injectable, nonenzymatic glucose biosensing platform that uses NIR fluorescence from a PEGylated-ConA and Cy5.5-β-mannopentaose complex”
2

Study evidence

Cy5.5-α-mannopentaose was prepared as a control and is reported to be ~10× costlier than Cy5.5-β-mannopentaose.10×

“As a control, an analogous assay was prepared with the α-anomeric form (i.e., Cy5.5-α-mannopentaose), which is 10X costlier.”
Claim 2 of 5SupportedIn a study published in ACS Measurement Science Au, the team found that a sensing material costing roughly one-tenth as much as a commonly used alternative delivered similar performance.View evidenceHide evidence

As statedroughly one-tenth as much

Why this verdict

The profile supports publication-level findings that β-mannopentaose was a lower-cost ligand option, with the α-anomer reported as roughly 10× costlier, and that β and α conjugates had comparable responsiveness across physiological glucose concentrations in vitro. The story's 'similar performance' wording is consistent with the abstract-level comparative responsiveness and binding-affinity evidence.

1

Study evidence

Developed an in vitro, nonenzymatic NIR fluorescence glucose sensing assay composed of PEGylated-ConA and Cy5.5-β-mannopentaose intended for injectable/minimally invasive continuous monitoring.

“novel, fully injectable, nonenzymatic glucose biosensing platform that uses NIR fluorescence from a PEGylated-ConA and Cy5.5-β-mannopentaose complex”
2

Study evidence

Cy5.5-α-mannopentaose was prepared as a control and is reported to be ~10× costlier than Cy5.5-β-mannopentaose.10×

“As a control, an analogous assay was prepared with the α-anomeric form (i.e., Cy5.5-α-mannopentaose), which is 10X costlier.”
Claim 3 of 5SupportedThe sensing platform is a nonenzymatic glucose-sensing system using near-infrared fluorescence and competitive binding with concanavalin A to measure glucose concentrations.View evidenceHide evidence

Why this verdict

The paper profile describes a fully injectable, nonenzymatic NIR fluorescence glucose biosensing platform based on PEGylated ConA and Cy5.5-β-mannopentaose. While the profile gives limited mechanistic detail at abstract depth, the ConA–mannopentaose glucose assay framing supports the story's description of a ConA binding-based NIR glucose-sensing system.

1

Study evidence

Developed an in vitro, nonenzymatic NIR fluorescence glucose sensing assay composed of PEGylated-ConA and Cy5.5-β-mannopentaose intended for injectable/minimally invasive continuous monitoring.

“novel, fully injectable, nonenzymatic glucose biosensing platform that uses NIR fluorescence from a PEGylated-ConA and Cy5.5-β-mannopentaose complex”
Claim 4 of 5SupportedThe researchers said β-mannopentaose, a less expensive material than α-mannopentaose, provided comparable sensing performance and also performed well in artificial interstitial fluid.View evidenceHide evidence

As statedroughly one-tenth as much

Why this verdict

The profile supports that β-mannopentaose was less expensive than the α-anomer control, that both conjugates showed comparable responsiveness across physiological glucose concentrations, and that β-mannopentaose showed reproducible/strong responsiveness in artificial interstitial fluid. The statement is appropriately hedged as a reported research finding.

1

Study evidence

Cy5.5-β-mannopentaose exhibits reproducible solvatochromism and strong responsiveness to glucose across 25–400 mg/dL when tested in artificial interstitial fluid, with maintained responsiveness within the physiologically relevant subcutaneous window.dynamic range 25–400 mg/dL

“performance was validated in artificial interstitial fluid”
2

Study evidence

Cy5.5-α-mannopentaose was prepared as a control and is reported to be ~10× costlier than Cy5.5-β-mannopentaose.10×

“As a control, an analogous assay was prepared with the α-anomeric form (i.e., Cy5.5-α-mannopentaose), which is 10X costlier.”
Claim 5 of 5SupportedThe sensing chemistry was incorporated into an injectable hydrogel that retained more than 94% of the sensing assay over seven days, but the technology remains at the proof-of-concept stage and will need further development before clinical use.View evidenceHide evidence

As statedmore than 94% ... over seven days

Why this verdict

The profile reports that Cy5.5-β-mannopentaose solution was housed in a hollow hydrogel rod and that more than 94% was retained over 7 days. It also supports the story's caveat that this remains proof-of-concept work requiring further development, because the abstract reports only in vitro/artificial interstitial fluid and hydrogel-retention data, with no in vivo or clinical validation.

1

Study evidence

Cy5.5-β-mannopentaose exhibits reproducible solvatochromism and strong responsiveness to glucose across 25–400 mg/dL when tested in artificial interstitial fluid, with maintained responsiveness within the physiologically relevant subcutaneous window.dynamic range 25–400 mg/dL

“performance was validated in artificial interstitial fluid”
2

Study evidence

Cy5.5-β-mannopentaose solution loaded into a hollow hydrogel rod retained >94% of the material over a 7-day period.>94% retained over 7 days

“Cy5.5-β-mannopentaose solution was placed in the cavity of a hollow hydrogel rod”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • Fluorescence anisotropy-informed computational model used to optimize assay component concentration ratios for physiological glucose detection.

    The profile identifies modeling and anisotropy-based optimization as a secondary contribution, but the story claims supplied here do not mention this methodological element.

    From Computational modeling informed by fluorescence anisotropy

5 things the story did carry across
  • Core assay: a fully injectable/intended minimally invasive, nonenzymatic NIR fluorescence glucose-sensing platform using PEGylated ConA and Cy5.5-β-mannopentaose.
  • β-mannopentaose versus α-mannopentaose comparison: α-anomer control was reported as about 10× costlier, while β showed comparable responsiveness/binding affinity and broader buffer dynamic range.
  • In vitro artificial interstitial fluid validation: β-mannopentaose showed reproducible solvatochromism and strong responsiveness across the tested blood-glucose range.
  • Hydrogel carrier feasibility: Cy5.5-β-mannopentaose solution housed in a hollow hydrogel rod retained more than 94% over 7 days.
  • Important limitation: all reported experimental evidence in the abstract is in vitro; no in vivo implantation, clinical testing, long-term biological fouling, or clinical-use performance is reported.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

5

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroDevelop a fully injectable, nonenzymatic NIR fluorescence ConA–mannopentaose glucose sensing assay and demonstrate sensitive glucose responsiveness across physiological ranges, emphasizing β‑anomeric mannopentaose as a lower-cost ligand.in vitroExpand

In plain English

In vitro proof-of-concept of a fully injectable, nonenzymatic NIR fluorescence glucose sensing assay composed of PEGylated-ConA and Cy5.5-β-mannopentaose. The assay was characterized by fluorescence anisotropy–informed optimization and glucose titrations, showing a broader buffer dynamic range for the β-anomer (25–400 mg/dL), comparable binding responsiveness to an α-anomer control, reproducible solvatochromic response in artificial interstitial fluid across the full blood glucose range, and >94% retention of Cy5.5-β-mannopentaose in a hollow hydrogel rod over 7 days. The authors highlight β-mannopentaose as a lower-cost ligand option for ConA-based continuous glucose monitoring platforms.

Key findings

  • Developed an in vitro, nonenzymatic NIR fluorescence glucose sensing assay composed of PEGylated-ConA and Cy5.5-β-mannopentaose intended for injectable/minimally invasive continuous monitoring.
  • Cy5.5-β-mannopentaose exhibited a broader dynamic range in buffer compared with the tested control.25–400 mg/dL (dynamic range reported for β-mannopentaose in buffer)
“novel, fully injectable, nonenzymatic glucose biosensing platform that uses NIR fluorescence from a PEGylated-ConA and Cy5.5-β-mannopentaose complex”
What this piece can’t prove
  • Retention testing limited to a single hydrogel rod construct over a 7-day interval as reported; longer-term stability and biological fouling in vivo are not reported.

2 further details could not be confirmed from the summary.

2in silicoOptimize/understand assay performance using fluorescence anisotropy and a computational model to set component concentration ratios for physiological glucose detection.Computational modeling informed by fluorescence anisotropyExpand

In plain English

The authors developed a computational model, parameterized/ informed by fluorescence anisotropy measurements, to optimize the concentration ratios of PEGylated-ConA and Cy5.5‑mannopentaose for sensitive glucose detection across the physiological range. The modeling/optimization was used to select assay component ratios that produced responsive signals in buffer and artificial interstitial fluid, and supported identification of a lower‑cost β‑anomer ligand with a broad dynamic range (25–400 mg/dL).

Key findings

  • A computational model parameterized by fluorescence anisotropy measurements was developed to optimize the concentration ratios of PEGylated‑ConA and Cy5.5‑mannopentaose for sensitive glucose detection within the physiological range.
  • Both α- and β‑anomer Cy5.5‑mannopentaose conjugates demonstrated comparable responsiveness across physiological glucose concentrations; Cy5.5‑β‑mannopentaose showed a broader dynamic range in buffer.dynamic range 25–400 mg/dL (β‑anomer, in buffer)
“Using fluorescence anisotropy, a computational model was developed to optimize the concentration ratios of assay components for sensitive glucose detection within the physiological range.”
What this piece can’t prove
  • Unclear how fluorescence anisotropy data were processed or incorporated into the model (e.g., which parameters were constrained or estimated).

3 further details could not be confirmed from the summary.

3in vitroDemonstrate robustness/translation-enabling properties: validate performance in artificial interstitial fluid (incl. solvatochromism across relevant glucose ranges) and show feasibility of housing the assay in a membrane/hydrogel carrier with high retention over time.in vitro matrix validation and hydrogel retention testExpand

In plain English

In vitro validation in artificial interstitial fluid (AISF) showed that the Cy5.5-β-mannopentaose:PEGylated-ConA NIR fluorescence assay exhibits reproducible solvatochromism and strong responsiveness across the full tested blood-glucose range (25–400 mg/dL), including the physiologically relevant subcutaneous window. Separately, the Cy5.5-β-mannopentaose solution housed in the cavity of a hollow antifouling hydrogel rod exhibited >94% retention over 7 days, supporting feasibility of membrane/hydrogel housing for minimally invasive deployment.

Key findings

  • Cy5.5-β-mannopentaose exhibits reproducible solvatochromism and strong responsiveness to glucose across 25–400 mg/dL when tested in artificial interstitial fluid, with maintained responsiveness within the physiologically relevant subcutaneous window.dynamic range 25–400 mg/dL
  • When housed in the cavity of a hollow hydrogel rod with antifouling properties and known mesh size, the Cy5.5-β-mannopentaose solution showed >94% retention over a 7-day period.>94% retained over 7 days
“performance was validated in artificial interstitial fluid”
What this piece can’t prove
  • All reported tests are in vitro (artificial interstitial fluid and hydrogel rod); no in vivo or clinical validation is reported in this unit.

2 further details could not be confirmed from the summary.

4in vitroDemonstrate robustness/translation-enabling properties: validate performance in artificial interstitial fluid (incl. solvatochromism across relevant glucose ranges) and show feasibility of housing the assay in a membrane/hydrogel carrier with high retention over time.hydrogel retention testExpand

In plain English

The authors evaluated feasibility of housing the Cy5.5-β-mannopentaose assay in a hollow hydrogel rod and report that >94% of the assay solution was retained in the rod cavity over a 7-day in vitro period; the hydrogel is described as having antifouling properties and a defined mesh size.

Key findings

  • Cy5.5-β-mannopentaose solution loaded into a hollow hydrogel rod retained >94% of the material over a 7-day period.>94% retained over 7 days
“Cy5.5-β-mannopentaose solution was placed in the cavity of a hollow hydrogel rod”
What this piece can’t prove
  • Unknown sample size, number of replicates, measurement technique for retention, and environmental conditions during the 7-day period.
  • Findings are limited to in vitro/hydrogel carrier evaluation and do not address in vivo durability or biocompatibility.

1 further detail could not be confirmed from the summary.

5in vitroBenchmark β‑ vs α‑anomeric mannopentaose conjugates (including cost and performance comparisons) as a control/alternative ligand choice.Comparative in vitro fluorescence titration/control assayExpand

In plain English

The study prepared an α‑anomeric control (Cy5.5-α-mannopentaose; reported as ~10× costlier) and directly compared it to Cy5.5-β-mannopentaose in in vitro fluorescence-based glucose assays. Both conjugates exhibited comparable responsiveness across physiological glucose concentrations, while the β-anomer showed a broader dynamic range in buffer (reported 25–400 mg/dL) and comparable binding affinity; validation in artificial interstitial fluid and additional device-relevant tests were reported for the β-anomer but not for the α-anomer in the abstract.

Key findings

  • Cy5.5-α-mannopentaose was prepared as a control and is reported to be ~10× costlier than Cy5.5-β-mannopentaose.10×
  • Both α- and β-conjugates demonstrated comparable responsiveness across physiological glucose concentrations in the reported in vitro assays.
“As a control, an analogous assay was prepared with the α-anomeric form (i.e., Cy5.5-α-mannopentaose), which is 10X costlier.”
What this piece can’t prove

3 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

ManDH5 E303Q in complex with mannopentaose after co-crystalliztion with mannopentaose at 1.6 angstroms resolution a beta-D-Mannanase of GH5 family from Dictyoglomus thermophilium

Worldwide Protein Data Bank · 2025 · Crossref

Source (opens in a new tab)

And 9 more candidates considered.